Effects of a New Oral Contraceptive Containing an Antimineralocorticoid Progestogen, Drospirenone, on the Renin-Aldosterone System, Body Weight, Blood Pressure, Glucose Tolerance, and Lipid Metabolism.
Journal of Clinical Endocrinology and Metabolism - United States
doi 10.1210/jcem.80.6.7775629
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 1995
Authors
Publisher
The Endocrine Society